Stephanie Gratton

Altus Drug Development

Leveraging our 20 years plus history of 505(b)(2), Hybrid and Complex Generic approvals, Altus Drug Development designs, develops and delivers new Value-Added Medicines to pharma companies seeking cost-effective ways to compete in today's challenging market. Simple reformulations fill the gap between high risk NCE's and low-return generics. Altus' Value Added Medicines go further, providing patent-protected label differentiated benefits to improve the lives of patients, offer new options to physicians and enhance your bottom line. Contact us today to learn how Altus can unlock the value in mature pipelines and expand existing portfolios with differentiated new products.